PHS
INBX icon

PFM Health Sciences’s Inhibrx INBX Stock Holding History

PFM Health Sciences’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.5M Buy
305,431
+39,914
+15% +$2.96M 1.87% 14
2025
Q4 		$21M Buy
265,517
+25,873
+11% +$1.76M 2.09% 15
2025
Q3 		$8.07M Sell
239,644
-4,617
-2% -$114K 0.62% 43
2025
Q2 		$3.49M Sell
244,261
-195,022
-44% -$2.52M 0.3% 46
2025
Q1 		$6.15M Buy
439,283
+303,737
+224% +$4.12M 0.45% 40
2024
Q4 		$2.09M Hold
135,546
– – 0.13% 72
2024
Q3 		$2.12M Hold
135,546
– – 0.12% 67
2024
Q2 		$1.92M Buy
+135,546
New +$2.12M 0.1% 71

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PFM Health Sciences's INBX Position: Q1 2026 in Review

PFM Health Sciences increased its Inhibrx (INBX) stake by 15% in Q1 2026, buying an estimated $2.96M and bringing the position to 305,431 shares worth $20.5M. The position accounts for 1.87% of the portfolio, ranked #14.

PFM Health Sciences first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $21M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • PFM Health Sciences held 305,431 shares of Inhibrx worth $20.5M as of Q1 2026.
  • PFM Health Sciences bought 39,914 Inhibrx shares in Q1 2026, an estimated $2.96M.
  • Inhibrx made up 1.87% of PFM Health Sciences's portfolio in Q1 2026, its #14 holding.
  • PFM Health Sciences first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • PFM Health Sciences's Inhibrx position peaked at $21M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.